Intraperitoneal Mitoxantrone or Floxuridine: Effects on Time-to-Failure and Survival in Patients with Minimal Residual Ovarian Cancer after Second-Look Laparotomy—A Randomized Phase II Study by the Southwest Oncology Group

Fm, Muggia; Liu, P.Y.; Alberts, David S.; Wallace, Darryl L.; O’Toole, Robert V.; Terada, Keith Y.; Franklin, Ernest W.; Herrer, Grant W.; Goldberg, David; Hannigan, Edward V.

doi:10.1006/gyno.1996.0163

Cited by 46 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results of second-line chemotherapy for ovarian cancer with i.p. floxuridine have been encouraging with a reported median survival of 38 months in patients with minimal residual disease following second-look laparotomy (20). Although i.p.…”

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Morgan

Synold

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To determine the maximally tolerated dose, toxicity, and pharmacokinetics of i.p.gemcitabine. Experimental Design: Patients had peritoneal carcinomatosis. Gemcitabine (40, 80, 120, or 160 mg/m 2 ) was administered into the peritoneal cavity in 2 L of warmed saline on days 1, 4, 8, and 12 of a 28-day cycle. Results:Thirty patients received 63 (median, 2; range, 0-6) courses.Tumors included ovary (14), uterus (2), colon (6), pancreas (3), and others (5). Dose-limiting toxicity included nausea, vomiting, diarrhea, dyspnea, fatal respiratory failure, and grade 3 elevation of alanine aminotransferase in three patients. Hematologic toxicity and pain were Vgrade 2. Three patients had decreased or resolved ascites. Of 19 patients evaluable for response, 10 had stable disease (median, 3.5 courses) and 9 had progressive disease. The median peak peritoneal concentration was1,116-fold (range, 456-1,886) higher than the peak plasma level. Plasma and peritoneal levels were undetectable within 8 to 12 h. At 120 mg/m 2 , the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL Â h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL Â h (range, 47.6-259.5). The mean peritoneal advantage (AUC peritoneal / AUC plasma ) was 847 (range, 356-1,385).

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Morgan

Synold

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Indeed, we recently reported that PARP inhibitors synergize remarkably with FdUrd, with toxicities that exceed those seen with other chemotherapy agents used to treat ovarian cancer. Accordingly, such results suggest that combining FdUrd with PARP inhibitors may be worthy of clinical studies, especially in ovarian cancer in which both FdUrd and PARP inhibitors have activity as single agents (Muggia et al, 1996;Kummar et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination

et al. 2012

View full text Add to dashboard Cite

“…IP carboplatin yielded satisfactory results by itself and in combination with IP etoposide [27,28]. FUDR, developed initially as IP consolidation for gastrointestinal cancer, was chosen for further study in a 'pick the winner' design in SWOG-8835 that also tested IP mitoxantrone for consolidation following positive reassessment in ovarian cancer [29]. Subsequently, IP FUDR was given in combination with IP cisplatin and/or carboplatin [30] and other IP platinum-containing regimens were tested building on Howell's initial experience [31], but limited conclusions can be drawn from nonrandomized trials.…”

Section: New Chemotherapy Regimensmentioning

confidence: 99%

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Alberts

Markman²,

Fm³

et al. 2006

Gynecologic Oncology

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a third phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on Intraperitoneal Therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop.

show abstract

Intraperitoneal Mitoxantrone or Floxuridine: Effects on Time-to-Failure and Survival in Patients with Minimal Residual Ovarian Cancer after Second-Look Laparotomy—A Randomized Phase II Study by the Southwest Oncology Group

Cited by 46 publications

References 3 publications

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Contact Info

Product

Resources

About